Pharmaceuticals
-
Pending Patent Legislation: What to Expect if It PassesOctober 9, 2025 | Gibbons
In 2025, Congress is occupied with serious legislative issues, among which are some pending patent i...
-
DNJ Court Denies Motion to Amend Invalidity and Non-Infringement Contentions Citing Lack of Diligence
June 13, 2025 | Gibbons
In IBSA Institut Biochimique SA v. Accord Healthcare, Inc., the United States District Court for the...
-
District of Delaware Court Dismisses, with Prejudice, Claims Withdrawn Pursuant to Case Narrowing Order
November 18, 2024 | Gibbons
In Exeltis USA Inc. v. Lupin Ltd., the United States District Court for the District of Delaware rec...
-
Edwards Lifesciences Corp. v. Meril Life Sciences Pvt. Ltd.: Should “Intent” Be Reconsidered in 271(e)(1)?
April 9, 2024 | Customs
Edwards Lifesciences Corp. v. Meril Life Sciences Pvt. Ltd., Appeal No. 22-1877 (Fed. Cir. March 25,...
-
Baxalta Inc. v. Genentech, Inc.: The Federal Circuit Addresses Enablement After Amgen v. Sanofi
September 28, 2023 | Biotech
Baxalta Inc., v. Genentech, Inc., Appeal No. 2022-1461 (Fed. Cir. Sept. 20, 2023) is another in the...
-
The District of Delaware Adopts the Federal Circuit’s Factors in Rejecting Regulatory Bar in a Protective Order
August 30, 2023 | Gibbons
In Amicus Therapeutics US, LLC v. Teva Pharmaceuticals USA, Inc., United States Magistrate Judge Chr...
